Arbutus reports Q1 2024 net loss of $17.9M, cash runway extended to Q2 2026

Arbutus Biopharma Corp

2024-Q1 EPS reported -$0.10 revenue$1,532,000

Net loss $17.9M ($0.10 per share); revenue $1.5M, down from $6.7M YoY due to lower license and royalty revenue.
Cash, equivalents & marketable securities $137.9M; expects cash runway through Q2 2026.
End-of-treatment data for two Phase 2a imdusiran trials to be presented at EASL June 2024.
AB-101 oral PD-L1 inhibitor Part 1 showed dose-dependent receptor occupancy; moving to multiple-ascending dose part.
Favorable claim construction ruling in Moderna LNP lawsuit; trial set for April 21, 2025.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Arbutus Biopharma Corp reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 2, 2024, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and certain other information.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001171843-24-002453

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.